Australian Studies Confirm Anisina as Potential Important New Weapon Against Melanoma

- Anisina kills melanoma cells regardless of their mutation status
- Melanoma cells with normal and mutated BRAF gene killed by Anisina
- Anisina to come into the clinic as a new weapon against melanoma

SYDNEY, April 9, 2015 US-Australian drug discovery company, Novogen (NRT:ASX; NVGN: NASDAQ), today announced that studies conducted at The University of Queensland Diamantina Institute (UQDI) revealed that experimental drug, Anisina, killed melanoma cells irrespective of their mutational status.

The significance of this finding lies in the fact that melanoma is associated with a variety of mutations, with those to the BRAF gene being the most prominent. A mutation to the BRAF gene occurs in about half of all melanoma patients and two drugs that target that mutation (vemurafenib and dabrafenib) have come to market in recent times.